Showing results (1-10 of 9) with videos related to
Sort By:
Pageof 1
Vaccine|May 1, 2012
Pneumococcal polysaccharide 23-valent vaccine: long-term persistence of circulating antibody and immunogenicity and safety after revaccination in adultsJohn D Grabenstein, Susan B ManoffJournal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|December 3, 2014
Advances in the understanding, management, and prevention of dengueLaura L Hermann, Swati B Gupta, Susan B Manoff, et al.Human Vaccines|August 24, 2011
Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adultsDaniel M Musher, Susan B Manoff, Richard D McFetridge, et al.The Journal of Infectious Diseases|January 22, 2010
Revaccination with a 23-valent pneumococcal polysaccharide vaccine induces elevated and persistent functional antibody responses in adults aged 65 > or = yearsSusan B Manoff, Charles Liss, Michael J Caulfield, et al.Human Vaccines & Immunotherapeutics|November 15, 2018
Immunogenicity and safety of an investigational tetravalent recombinant subunit vaccine for dengue: results of a Phase I randomized clinical trial in flavivirus-naïve adultsSusan B Manoff, Michele Sausser, Amy Falk Russell, et al.Vaccine|September 11, 2012
Measles, mumps, and rubella virus vaccine (M-M-R™II): a review of 32 years of clinical and postmarketing experienceFabio Lievano, Susan A Galea, Michele Thornton, et al.Human Vaccines & Immunotherapeutics|March 23, 2016
Vaccination of adults with 23-valent pneumococcal polysaccharide vaccine induces robust antibody responses against pneumococcal serotypes associated with serious clinical outcomesKaren L Ciprero, Rocio D Marchese, Patrick Richard, et al.Vaccine|October 14, 2015
Preclinical and clinical development of a dengue recombinant subunit vaccineSusan B Manoff, Sarah L George, Andrew J Bett, et al.The Journal of Infectious Diseases|August 3, 2013
Safety and immunogenicity of heat-treated zoster vaccine (ZVHT) in immunocompromised adultsKathleen M Mullane, Drew J Winston, Michael S Wertheim, et al.Pageof 1